Literature DB >> 8775507

Antigonococcal activity of 11 drugs used for therapy or prophylaxis of malaria.

P C Mehaffey1, M S Barrett, S D Putnam, R N Jones.   

Abstract

Antibacterial agents are often used in malarial endemic areas for antimalarial prophylaxis (such as doxycycline and clindamycin). Gonococcal infections may coexist in the same geographic area, thus becoming suppressed by compounds directed toward malarial parasites. We tested 11 drugs with activity for Plasmodium species against 105 Neisseria gonorrhoeae strains. Traditional or investigational antimalarials such as arteflene (Ro 42-1611), chloroquine, primaquine, pyrimethamine, quinacrine, and quinine were observed to be inactive. Fansidar (sulfadoxine-pyrimethamine) and mefloquine possess marginal action in a minority of gonococcus strains (< 10%). Doxycycline [minimum inhibitory concentration inhibiting 90% of tested strains (MIC 90) 2 micrograms/ml] and azithromycin (MIC 90, 0.5 microgram/ml) among the antibacterials were very active, indicating a dual role as antimalarial and antigonococcal agents. Thus, the gonorrhea and sexually transmitted disease epidemiologic data from geographic regions where doxycycline or newer macrolides may be used for malarial prophylaxis or therapy could be significantly altered.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8775507     DOI: 10.1016/0732-8893(95)00148-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  2 in total

1.  Antimicrobial activities of mefloquine and a series of related compounds.

Authors:  C M Kunin; W Y Ellis
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Anti-bacterial activity of intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of sulphadoxine-pyrimethamine, mefloquine, and azithromycin.

Authors:  Mesküre Capan; Ghyslain Mombo-Ngoma; Athanasios Makristathis; Michael Ramharter
Journal:  Malar J       Date:  2010-10-29       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.